|1.||Achan, Jane: 9 articles (04/2015 - 11/2012)|
|2.||Kamya, Moses R: 7 articles (04/2015 - 11/2012)|
|3.||Domingo, Pere: 6 articles (07/2015 - 01/2007)|
|4.||Plenty, Albert: 6 articles (04/2015 - 08/2013)|
|5.||Clark, Tamara D: 6 articles (04/2015 - 11/2012)|
|6.||Maartens, Gary: 6 articles (02/2015 - 04/2008)|
|7.||McIlleron, Helen: 6 articles (01/2014 - 10/2010)|
|8.||Pulido, Federico: 5 articles (07/2015 - 05/2005)|
|9.||Arribas, José R: 5 articles (07/2015 - 11/2006)|
|10.||Havlir, Diane V: 5 articles (04/2015 - 08/2013)|
03/08/2002 - "Inflammatory oedema associated with lopinavir-including HAART regimens in advanced HIV-1 infection: report of 3 cases."
01/01/2013 - "Using quantitative assays in cell line and primary cell systems that directly measure the early steps of HIV-1 infection we find that the PIs Lopinavir and Darunavir are equally potent against both cell-free and cell-to-cell spread of HIV-1. "
10/01/2010 - "Lopinavir/ritonavir, in combination with other ART agents, is a well established and cost-effective treatment for both ART-naive and -experienced patients with HIV-1 infection and, with successful management of adverse events, continues to have a role as an effective component of ART regimens for the control of HIV-1 infection."
11/01/2014 - "[Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection]."
09/01/2014 - "This study aimed to assess the cost effectiveness of the darunavir/r regimen compared with the lopinavir/r regimen in treatment-naive adults with HIV-1 infection in Canada. "
|2.||HIV Infections (HIV Infection)
09/22/2014 - "Moreover, the tissue distribution study showed a higher distribution of Lopinavir loaded nanoparticles to lymphoid organs (liver, spleen and lymph nodes that are also important viral reservoirs in HIV infection). "
01/01/2008 - "This study investigated changes in lipid levels, comparing patients with HIV infection alone and those with HCV too, in the lopinavir/r cohort of the SCOLTA project. "
09/22/2014 - "Thus, we conclude that Lopinavir loaded nanoparticle could be a superior alternative approach to free Lopinavir in treating HIV infection."
01/01/2015 - "The protease inhibitor lopinavir, used for the treatment of HIV infections, triggers suicidal death or apoptosis of nucleated cells. "
09/01/2013 - "Despite the known benefits and the experienced use of lopinavir/ritonavir (LPV/r) in the management of HIV infection, important interindividual variability in the pharmacokinetics (PKs) and the response to treatment with standard doses of this drug has been observed. "
10/01/2015 - "We report here that lopinavir blocks glucose uptake into isolated malaria parasites at therapeutically relevant drug levels. "
04/24/2015 - "The Prevention of Malaria and HIV Disease in Tororo trial (NCT00993031) enrolled HIV-infected pregnant Ugandan women at 12-28 weeks gestation who were randomized to lopinavir or efavirenz-based antiretroviral therapy (ART). "
12/15/2014 - "We sought to evaluate whether lopinavir/ritonavir-based antiretroviral therapy (ART) reduced the risk of placental malaria. "
01/01/2014 - "Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?"
08/15/2013 - "HIV-infected pregnant women were randomized to lopinavir/ritonavir- or efavirenz-based therapy in a larger trial (the Prevention of Malaria and HIV disease in Tororo, PROMOTE). "
10/01/2003 - "Diarrhea related to lopinavir is most often mild and not related to plasma drug levels."
07/01/2012 - "The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. "
07/01/2012 - "Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants."
06/01/2011 - "Boosted darunavir was generally well tolerated, with lower incidence of diarrhea and a more favorable lipid profile than boosted lopinavir in treatment-naive patients."
02/01/2009 - "In drug-naïve subjects, regimens based on ATV/r have shown non-inferiority compared to lopinavir (LPV)/r (CASTLE study) or fosamprenavir/r (ALERT trial), generally with improved tolerance (less diarrhea and dyslipidemia). "
06/01/2015 - "With respect to categorical variables, a significant association was found for the presence of diabetes (P=0.006), hypertension (P<0.001), facial lipodystrophy (P=0.031), and the use of lopinavir (P=0.042). "
04/01/2010 - "Lopinavir/ritonavir plasma levels were correlated with an increase in lipodystrophy. "
06/01/2010 - "In this study, factors related to antiretroviral therapy were the main risk factors for lipodystrophy, corroborating the literature, but the findings also point to the need for further exploration into some of these associations, especially with the use of didanosine and lopinavir/ritonavir, which are less frequently reported. "
08/01/2010 - "Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy."
07/01/2012 - "Data show that lopinavir/ritonavir resulted in manifestations of lipodystrophy, insulin resistance, and hyperlipidemia. "
|5.||Protease Inhibitors (Protease Inhibitor)
|1.||Highly Active Antiretroviral Therapy (HAART)
|4.||Drug Therapy (Chemotherapy)